E
iTeos Therapeutics, Inc.
ITOS
$7.19
-$0.33-4.39%
E
Sell
3/5/2025Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to E+ from D- on 3/5/2025 due to a noticeable decline in the solvency index, volatility index and total return index. The quick ratio declined from 14.44 to 12.35.
iTeos Therapeutics, Inc. (ITOS) was downgraded to E+ from D- on 3/5/2025 due to a noticeable decline in the solvency index, volatility index and total return index. The quick ratio declined from 14.44 to 12.35.
D
Sell
2/11/2025Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to D- from E+ on 2/11/2025 due to an increase in the volatility index.
iTeos Therapeutics, Inc. (ITOS) was upgraded to D- from E+ on 2/11/2025 due to an increase in the volatility index.
E
Sell
1/27/2025Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to E+ from D- on 1/27/2025 due to a decline in the volatility index and total return index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to E+ from D- on 1/27/2025 due to a decline in the volatility index and total return index.
D
Sell
1/6/2025Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
iTeos Therapeutics, Inc. (ITOS) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
E
Sell
10/31/2024Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to E+ from D- on 10/31/2024 due to a noticeable decline in the volatility index and total return index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to E+ from D- on 10/31/2024 due to a noticeable decline in the volatility index and total return index.
D
Sell
8/15/2024Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to D- from D on 8/15/2024 due to a significant decline in the efficiency index, valuation index and solvency index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to D- from D on 8/15/2024 due to a significant decline in the efficiency index, valuation index and solvency index.
D
Sell
5/17/2023Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to D from C- on 5/17/2023 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 238.71% from $17.73M to -$24.59M, earnings per share declined from $0.5492 to -$0.44, and net income declined 176.03% from $20.45M to -$15.55M.
iTeos Therapeutics, Inc. (ITOS) was downgraded to D from C- on 5/17/2023 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 238.71% from $17.73M to -$24.59M, earnings per share declined from $0.5492 to -$0.44, and net income declined 176.03% from $20.45M to -$15.55M.
C
Hold
5/3/2023Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to C- from D+ on 5/3/2023 due to an increase in the volatility index.
iTeos Therapeutics, Inc. (ITOS) was upgraded to C- from D+ on 5/3/2023 due to an increase in the volatility index.
D
Sell
4/14/2023Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to D+ from C- on 4/14/2023 due to a decline in the volatility index and total return index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to D+ from C- on 4/14/2023 due to a decline in the volatility index and total return index.
C
Hold
3/31/2023Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to C- from C on 3/31/2023 due to a decline in the total return index and volatility index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to C- from C on 3/31/2023 due to a decline in the total return index and volatility index.
C
Hold
3/16/2023Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to C from C- on 3/16/2023 due to a large increase in the growth index, solvency index and volatility index. Earnings per share increased from $0.0279 to $0.5492, EBIT increased 218.79% from -$14.92M to $17.73M, and total revenue increased 176.62% from $19.49M to $53.91M.
iTeos Therapeutics, Inc. (ITOS) was upgraded to C from C- on 3/16/2023 due to a large increase in the growth index, solvency index and volatility index. Earnings per share increased from $0.0279 to $0.5492, EBIT increased 218.79% from -$14.92M to $17.73M, and total revenue increased 176.62% from $19.49M to $53.91M.
C
Hold
1/17/2023Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to C- from D+ on 1/17/2023 due to an increase in the volatility index and total return index.
iTeos Therapeutics, Inc. (ITOS) was upgraded to C- from D+ on 1/17/2023 due to an increase in the volatility index and total return index.
D
Sell
11/14/2022Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to D+ from C- on 11/14/2022 due to a large decline in the growth index and total return index. EBIT declined 511.39% from $3.63M to -$14.92M, earnings per share declined from $0.15 to $0.0279, and total revenue declined 53.29% from $41.72M to $19.49M.
iTeos Therapeutics, Inc. (ITOS) was downgraded to D+ from C- on 11/14/2022 due to a large decline in the growth index and total return index. EBIT declined 511.39% from $3.63M to -$14.92M, earnings per share declined from $0.15 to $0.0279, and total revenue declined 53.29% from $41.72M to $19.49M.
C
Hold
10/17/2022Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to C- from D+ on 10/17/2022 due to an increase in the total return index, valuation index and volatility index.
iTeos Therapeutics, Inc. (ITOS) was upgraded to C- from D+ on 10/17/2022 due to an increase in the total return index, valuation index and volatility index.
D
Sell
8/8/2022Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to D+ from C- on 8/8/2022 due to a noticeable decline in the total return index, valuation index and volatility index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to D+ from C- on 8/8/2022 due to a noticeable decline in the total return index, valuation index and volatility index.
C
Hold
7/11/2022Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to C- from C on 7/11/2022 due to a noticeable decline in the total return index, volatility index and valuation index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to C- from C on 7/11/2022 due to a noticeable decline in the total return index, volatility index and valuation index.
C
Hold
5/31/2022Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to C from C+ on 5/31/2022 due to a decline in the volatility index and total return index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to C from C+ on 5/31/2022 due to a decline in the volatility index and total return index.
C
Hold
5/13/2022Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to C+ from C on 5/13/2022 due to a substantial increase in the efficiency index and valuation index. Total capital increased 13.16% from $558.16M to $631.63M.
iTeos Therapeutics, Inc. (ITOS) was upgraded to C+ from C on 5/13/2022 due to a substantial increase in the efficiency index and valuation index. Total capital increased 13.16% from $558.16M to $631.63M.
C
Hold
3/25/2022Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to C from D+ on 3/25/2022 due to a significant increase in the valuation index, growth index and solvency index. EBIT increased 167.96% from $79.58M to $213.23M, earnings per share increased from $1.86 to $4.805, and total revenue increased 130.65% from $104.27M to $240.5M.
iTeos Therapeutics, Inc. (ITOS) was upgraded to C from D+ on 3/25/2022 due to a significant increase in the valuation index, growth index and solvency index. EBIT increased 167.96% from $79.58M to $213.23M, earnings per share increased from $1.86 to $4.805, and total revenue increased 130.65% from $104.27M to $240.5M.
D
Sell
2/16/2022Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to D+ from C- on 2/16/2022 due to a decline in the total return index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to D+ from C- on 2/16/2022 due to a decline in the total return index.
C
Hold
1/14/2022Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to C- from D+ on 1/14/2022 due to a major increase in the efficiency index, total return index and growth index. Operating cash flow increased 3,414.17% from -$18.26M to $605M, EBIT increased 372.34% from -$29.22M to $79.58M, and net income increased 363.21% from -$26.46M to $69.64M.
iTeos Therapeutics, Inc. (ITOS) was upgraded to C- from D+ on 1/14/2022 due to a major increase in the efficiency index, total return index and growth index. Operating cash flow increased 3,414.17% from -$18.26M to $605M, EBIT increased 372.34% from -$29.22M to $79.58M, and net income increased 363.21% from -$26.46M to $69.64M.
D
Sell
11/9/2021Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to D+ from D- on 11/9/2021 due to an increase in the total return index.
iTeos Therapeutics, Inc. (ITOS) was upgraded to D+ from D- on 11/9/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
iTeos Therapeutics, Inc. (ITOS) was downgraded to D- from D+ on 11/8/2021 due to a decline in the valuation index.
iTeos Therapeutics, Inc. (ITOS) was downgraded to D- from D+ on 11/8/2021 due to a decline in the valuation index.
D
Sell
11/3/2021Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to D+ from D on 11/3/2021 due to a large increase in the total return index and solvency index.
iTeos Therapeutics, Inc. (ITOS) was upgraded to D+ from D on 11/3/2021 due to a large increase in the total return index and solvency index.
D
Sell
5/13/2021Upgraded
iTeos Therapeutics, Inc. (ITOS) was upgraded to D from E on 5/13/2021 due to a significant increase in the solvency index, growth index and total return index. Operating cash flow increased 46.59% from -$10.23M to -$5.46M, and earnings per share increased from -$0.4783 to -$0.4244.
iTeos Therapeutics, Inc. (ITOS) was upgraded to D from E on 5/13/2021 due to a significant increase in the solvency index, growth index and total return index. Operating cash flow increased 46.59% from -$10.23M to -$5.46M, and earnings per share increased from -$0.4783 to -$0.4244.
E
Sell
10/16/2020None
iTeos Therapeutics, Inc. (ITOS) was downgraded to E from U on 10/16/2020.
iTeos Therapeutics, Inc. (ITOS) was downgraded to E from U on 10/16/2020.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
